This is good news for countless men, especially older men, as premature ejaculation is one of the most common sex-related complaints about aging (that and erectile dysfunction, the inability to maintain an erection).
The advance in this treatment, which just completed a phase 3 clinical trial, is that it selectively desensitizes specific cells on the penis, thereby delaying ejaculation without impacting the sensation of ejaculation. This is an advance from current treatments that generally desensitize the penis and, therefore, also reduce the pleasure of sex. Another advantage of this new treatment is that it can be applied 5 minutes before sex.
The spray is called PSD502, for now, and was tested in a controlled study of 300 men with premature ejaculation. On average, the men in the study ejaculated in 0.6 minutes. Half were assigned PSD502 and half were given a placebo spray. The PSD502 group improved to 4 minutes.
While this is promising news, keep in mind that it won't be available until the U.S. Food and Drug Administration approves it for use.
Read More on Sex and Aging (for men) and Sex Tips (for the older man)
Source: Wyllie, M; Heath, P; Dinsmore, W. PSD502, a novel metered-dose aerosol formulation of lidocaine and prilocaine, is a safe and effective treatment for premature ejaculation (PE); results of a phase III, randomized, double-blind, placebo-controlled study. J Urol, suppl. 2009: 181, 4, abstract 1370.
